Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Control of the Immune Response B and Lymphoproliferation, Joint Research Unit CNRS 7276, INSERM 1262, University of Limoges, Limoges, France; Centre de Référence de l'Amylose AL et des autres Maladies par Dépôts d'Imunoglobuline Monoclonale, University Hospital Dupuytren, Limoges, France.
Kidney Int. 2024 Aug;106(2):201-213. doi: 10.1016/j.kint.2024.02.027. Epub 2024 May 7.
Monoclonal Ig crystalline nephropathies are rare lesions resulting from precipitation of monoclonal Igs in the kidney as crystalline inclusions. They can be categorized into lesions with predominant intracellular crystals (light chain [LC] proximal tubulopathy, LC crystal-storing histiocytosis, and LC crystalline podocytopathy) and lesions with predominant extracellular crystals (crystalglobulin-induced nephropathy and crystalline variant of LC cast nephropathy). The majority of these lesions are associated with low tumor burden lymphoproliferative disorders, with the exception of crystalline variant of LC cast nephropathy. Extrarenal involvement (e.g., skin and cornea) is frequent. Kidney biopsy is the cornerstone for diagnosis, which often requires electron microscopy and antigen retrieval. A thorough hematologic workup and evaluation of extrarenal involvement is mandatory for management. Treatment of these lesions is with clone-directed therapy, with the goal of achieving hematologic very good partial response or complete response, which preserves or improves kidney function. In vitro and in vivo studies, animal models, and novel sequencing techniques have been invaluable tools to understand the pathogenesis of LC proximal tubulopathy and can be used to increase our limited knowledge of the pathogenesis of the other monoclonal Ig crystalline nephropathies. This review provides an update on the pathology, renal and hematologic characteristics, extrarenal manifestations, prognosis, treatment, and pathogenesis of monoclonal Ig crystalline nephropathies.
单克隆免疫球蛋白结晶性肾病是一种罕见的病变,其特征是单克隆免疫球蛋白在肾脏中沉淀为结晶包涵体。这些病变可以分为以细胞内晶体为主的病变(轻链[LC]近曲小管病变、LC 晶体储存组织细胞增生症和 LC 晶体足细胞病)和以细胞外晶体为主的病变(结晶球蛋白诱导的肾病和 LC casts 肾病的结晶变体)。这些病变大多数与低肿瘤负荷的淋巴增生性疾病有关,LC casts 肾病的结晶变体除外。肾脏外受累(如皮肤和角膜)很常见。肾脏活检是诊断的基石,通常需要电子显微镜和抗原检索。为了管理这些病变,必须进行全面的血液学检查和肾脏外受累的评估。这些病变的治疗方法是采用克隆定向治疗,目标是实现血液学非常好的部分缓解或完全缓解,从而保持或改善肾功能。体外和体内研究、动物模型和新型测序技术已成为理解 LC 近曲小管病变发病机制的宝贵工具,并可用于增加我们对其他单克隆免疫球蛋白结晶性肾病发病机制的有限认识。本综述介绍了单克隆免疫球蛋白结晶性肾病的病理学、肾脏和血液学特征、肾脏外表现、预后、治疗和发病机制的最新进展。